EP0274176A3 - Sustained release capsule or tablet formulation - Google Patents

Sustained release capsule or tablet formulation Download PDF

Info

Publication number
EP0274176A3
EP0274176A3 EP87300887A EP87300887A EP0274176A3 EP 0274176 A3 EP0274176 A3 EP 0274176A3 EP 87300887 A EP87300887 A EP 87300887A EP 87300887 A EP87300887 A EP 87300887A EP 0274176 A3 EP0274176 A3 EP 0274176A3
Authority
EP
European Patent Office
Prior art keywords
sustained release
tablet formulation
release capsule
capsule
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87300887A
Other versions
EP0274176A2 (en
EP0274176B1 (en
Inventor
Seamus Mulligan
Randall T. Sparks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of EP0274176A2 publication Critical patent/EP0274176A2/en
Publication of EP0274176A3 publication Critical patent/EP0274176A3/en
Application granted granted Critical
Publication of EP0274176B1 publication Critical patent/EP0274176B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP87300887A 1987-01-09 1987-02-02 Sustained release capsule or tablet formulation Expired - Lifetime EP0274176B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE6487A IE59540B1 (en) 1987-01-09 1987-01-09 Sustained release capsule or tablet formulation
IE6487 1987-01-09

Publications (3)

Publication Number Publication Date
EP0274176A2 EP0274176A2 (en) 1988-07-13
EP0274176A3 true EP0274176A3 (en) 1988-09-14
EP0274176B1 EP0274176B1 (en) 1992-05-27

Family

ID=11006244

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87300887A Expired - Lifetime EP0274176B1 (en) 1987-01-09 1987-02-02 Sustained release capsule or tablet formulation

Country Status (12)

Country Link
EP (1) EP0274176B1 (en)
JP (1) JP2763879B2 (en)
AU (1) AU592618B2 (en)
CA (1) CA1288049C (en)
CS (1) CS417791A3 (en)
DE (1) DE3779414D1 (en)
DK (1) DK172893B1 (en)
ES (1) ES2042547T3 (en)
IE (1) IE59540B1 (en)
NZ (1) NZ219140A (en)
PH (1) PH23528A (en)
ZA (1) ZA87738B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2880021A (en) * 1954-03-12 1959-03-31 Herbert E White Telescopic pipe joint with tolerance accommodating means
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
ES2084478T3 (en) * 1992-02-17 1996-05-01 Siegfried Ag Pharma DOSAGE FORMS THAT HAVE PROLONGED RELEASE OF THE ACTIVE INGREDIENT.
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
CA2215921A1 (en) * 1995-03-29 1996-10-03 Hidekazu Syodai Gelatin capsules having adjusted water activity
DE19515972A1 (en) * 1995-05-02 1996-11-07 Bayer Ag Controlled release pharmaceutical preparations and process for their preparation
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
JP3893058B2 (en) 1999-09-30 2007-03-14 ペンウェスト ファーマシューティカルズ カンパニー Sustained release matrix system for highly soluble drugs
KR100396443B1 (en) * 2001-09-08 2003-09-02 한국유나이티드제약 주식회사 Solubilized Felodipine Containing Sustained Release Preparations and it's Manufacturing Process
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
CN101103964B (en) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 Sustained-release preparation containing felodipine and preparation method thereof
IE20100799A1 (en) * 2010-12-22 2012-08-01 Eurand Pharmaceuticals Ltd Pharmaceutical composites of poorly water soluble drugs and polymers
CN102188401B (en) * 2011-05-10 2013-07-03 山东威高药业有限公司 Felodipine sustained-release tablet and preparation method thereof
CN104758938B (en) * 2015-04-01 2017-08-29 新乡医学院第一附属医院 It is a kind of to treat felodipine tablet of hypertension and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0035142A2 (en) * 1980-02-22 1981-09-09 BASF Aktiengesellschaft Utilisation of micronized, crosslinked insoluble polyvinylpyrrolidone for the stabilisation of suspensions
EP0078430A2 (en) * 1981-10-29 1983-05-11 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
EP0167909A2 (en) * 1984-07-04 1986-01-15 Bayer Ag Solid pharmaceutical preparations containing dihydropyridine, and process for their manufacture

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA765931B (en) * 1975-10-10 1977-09-28 Squibb & Sons Inc Controlled release tablet
JPS5446837A (en) * 1977-09-19 1979-04-13 Kanebo Ltd Easily absorbable nifedipin composition, its preparation, and anti-stenocardia containing the same
DE3427402A1 (en) * 1984-07-25 1986-01-30 Bayer Ag, 5090 Leverkusen NEW COMBINATION DEVICE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE AS A MEDICINAL PRODUCT
JPS618A (en) * 1984-06-09 1986-01-06 Sawai Seiyaku Kk Nifedipin-containing drug preparation
JPS6115829A (en) * 1984-06-29 1986-01-23 Toyobo Co Ltd Sustained release nifedipine pharmaceutical for application to oral mucosa
JPS6117510A (en) * 1984-07-03 1986-01-25 Toyobo Co Ltd Gradually releasing preparation of nifedipine to be applied to oral cavity mucosa
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0035142A2 (en) * 1980-02-22 1981-09-09 BASF Aktiengesellschaft Utilisation of micronized, crosslinked insoluble polyvinylpyrrolidone for the stabilisation of suspensions
EP0078430A2 (en) * 1981-10-29 1983-05-11 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
EP0167909A2 (en) * 1984-07-04 1986-01-15 Bayer Ag Solid pharmaceutical preparations containing dihydropyridine, and process for their manufacture

Also Published As

Publication number Publication date
JPS63174929A (en) 1988-07-19
EP0274176A2 (en) 1988-07-13
IE870064L (en) 1988-07-09
NZ219140A (en) 1989-03-29
DK172893B1 (en) 1999-09-20
EP0274176B1 (en) 1992-05-27
AU592618B2 (en) 1990-01-18
DK52887A (en) 1988-07-10
DE3779414D1 (en) 1992-07-02
IE59540B1 (en) 1994-03-09
CS417791A3 (en) 1992-06-17
DK52887D0 (en) 1987-02-02
AU6820787A (en) 1988-07-14
PH23528A (en) 1989-08-25
JP2763879B2 (en) 1998-06-11
ZA87738B (en) 1987-09-30
ES2042547T3 (en) 1993-12-16
CA1288049C (en) 1991-08-27

Similar Documents

Publication Publication Date Title
EP0274176A3 (en) Sustained release capsule or tablet formulation
AR243378A1 (en) Sustained release pharmaceutical composition
ZA874315B (en) Sustained release capsule
ZA894020B (en) Controlled release pharmaceutical formulation
CY1741A (en) Sustained release matrix formulation
EP0297625A3 (en) Pressure-sensitive tablet
PH24205A (en) Sustained release dosage forms
ZA851891B (en) Sustained release pharmaceutical capsules
GB2190287B (en) Controlled release ketoprofen pharmaceutical formulation
GB8423572D0 (en) Sustained release pharmaceutical tablet
GB8712240D0 (en) Pharmaceutical formulation
AU106236S (en) Pharmaceutical tablet
IE872675L (en) Sustained release pharmaceutical
GB8721554D0 (en) Capsule formulation
CA59348S (en) Pharmaceutical tablet
IE871600L (en) Sustained release pharmaceutical preparation.
IE850698L (en) Sustained release pharmaceutical capsule
IE862306L (en) Controlled release tablet
GB8700063D0 (en) Pharmaceutical formulation
GB8706684D0 (en) Pharmaceutical formulation
GB8708011D0 (en) Pharmaceutical formulation
GB8706683D0 (en) Pharmaceutical formulation
GB8720073D0 (en) Pharmaceutical formulation
GB8718131D0 (en) Pharmaceutical formulation
GB8700239D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE ES FR GB IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): BE CH DE ES FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19890125

17Q First examination report despatched

Effective date: 19910129

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE ES FR GB IT LI NL SE

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REF Corresponds to:

Ref document number: 3779414

Country of ref document: DE

Date of ref document: 19920702

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2042547

Country of ref document: ES

Kind code of ref document: T3

EAL Se: european patent in force in sweden

Ref document number: 87300887.4

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050202

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20060116

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060217

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060223

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20060224

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20060227

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060316

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060331

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070203

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20070202

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20070203

BE20 Be: patent expired

Owner name: *ELAN CORP. P.L.C.

Effective date: 20070202

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20060227

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060228

Year of fee payment: 20

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20080301